Products for Research Use Only
RegisterLogin

Infigratinib phosphate

CAT: 0804-HY-13311A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13311A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
CAS Number
1310746-10-1
Product Name Alternative
BGJ-398 phosphate; NVP-BGJ398 (phosphate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
FGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NVP-BGJ398-phosphate.html
Concentration
10mM
Purity
99.59
Solubility
DMSO : 8.75 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=P(O)(O)O.ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O
Molecular Formula
C26H34Cl2N7O7P
Molecular Weight
658.47
Precautions
H302, H315, H319
References & Citations
[1]Guagnano V, et al. Discovery of 3- (2,6-Dichloro-3,5-dimethoxy-phenyl) -1-{6-[4- (4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T|[2]Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12 (5) :632-42.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
BioRxiv. 2025 Nov 14.|Ann Rheum Dis. 2016 May;75 (5) :883-90. |Anti-Cancer Drug. 2022 Dec.|Biochim Biophys Acta Mol Basis Dis. 2025 May 29:167940.|Biomed Pharmacother. 2025 Oct 21:192:118677.|Biomedicines. 2023 Nov 27;11 (12) :3155.|bioRxiv. 2024 May 14.|bioRxiv. 2025 Jun 16:2025.06.11.659120.|Biotechnol J. 2024 Aug;19 (8) :e2400278.|Cancer Discov. 2018 Mar;8 (3) :354-369.|Cancer Discov. 2019 Dec;9 (12) :1686-1695.|Cancers (Basel) . 2024 Jul 3;16 (13) :2447.|Cell Death Dis. 2025 Jul 2;16 (1) :485.|Cell Rep. 2024 Dec 30;44 (1) :115116.|Cell Rep. 2019 Feb 12;26 (7) :1709-1717.e3. |Chem Res Toxicol. 2021 Jul 19;34 (7) :1800-1813.|Department Biologie. Friedrich-Alexander University Erlangen-Nuremberg. March.10th.2016.|Development. 2025 May 15;152 (10) :dev204687. |FEBS Open Bio. 2023 May;13 (5) :804-817.|Heliyon. 2024 May 10.|J Control Release. 2018 Sep 28;286:254-263.|J Exp Clin Cancer Res. 2021 Aug 27;40 (1) :273.|J Med Chem. 2025 Mar 13;68 (5) :5907-5925.|J Neuroinflammation. 2023 Jan 17;20 (1) :10.|medRxiv. 2023 Mar 17.|Nat Commun. 2022 Aug 4;13 (1) :4534.|Nature. 2022 Aug;608 (7923) :609-617.|NPJ Precis Oncol. 2021 Jul 16;5 (1) :66.|Obesity (Silver Spring) . 2019 Mar;27 (3) :399-408.|Oncogene. 2016 Apr 28;35 (17) :2247-65.|Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20220175722A1.|Pharmaceutics. 2025 Oct 31;17 (11) :1415.|Res Sq. 2025 Jul 24.|RSC Adv. 2020,10, 16231-16244.|Sci Rep. 2016 Apr 28;6:25272.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2025 Nov 3;10 (1) :360.|Signal Transduct Target Ther. 2025 Nov 4;10 (1) :361.|The 22nd National Graduate Research Conference. 2021 Mar 25.|Thorac Cancer. 2025 Jan;16 (1) :e15488.|Tissue Eng Part A. 2019 Mar;25 (5-6) :437-445.|University of Auckland. 2025.|World J Exp Med. 2025 Jun 20;15 (2) :100443.

Related Products

CatalogName
HY-13311-01Infigratinib
HY-13311S-01Infigratinib-d3
HY-160124-01Infigratinib-Boc
HY-13311R-01Infigratinib (Standard)
HY-B0141BPolyestradiol (phosphate)
HY-B1064-01Clindamycin phosphate
HY-135317FEmavusertib (phosphate)
HY-14946AAmifampridine (phosphate)
HY-A0129-01Histamine (phosphate)
HY-P2943Phosphate acetyltransferase

Alternative Products

CatalogName
KCC74610-01Infigratinib phosphate
T1975-01Infigratinib
BA8959-25Infigratinib-Boc
MBS5813544Infigratinib mesylate
C08339-25mgInfigratinib (BGJ398)
GTR19208388-01Infigratinib acetate

Popular Products